Chapter 18. Molecular Biology of Hepatobiliary Cancer

  1. Janusz Jankowski MD, PhD, FRCP, FACG Consultant Gastroenterologist Fellow Professor2,3,4,5,6,
  2. Richard Sampliner MD Professor of Medicine Chief of Gastroenterology7,8,
  3. David Kerr CBE, MA, MD, DSc, FRCP, FMedSci Head of Department of Clinical Pharmacology6,9,10 and
  4. Yuman Fong MD Professor of Surgery11,12
  1. Knut Ketterer MD and
  2. Helmut Friess MD

Published Online: 14 JAN 2009

DOI: 10.1002/9781444300147.ch18

Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach

Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach

How to Cite

Ketterer, K. and Friess, H. (2008) Molecular Biology of Hepatobiliary Cancer, in Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach (eds J. Jankowski, R. Sampliner, D. Kerr and Y. Fong), Blackwell Publishing Ltd., Oxford, UK. doi: 10.1002/9781444300147.ch18

Editor Information

  1. 2

    Digestive Diseases Centre UHL Trust, Leicester, UK

  2. 3

    James Black Senior Fellow and Professor, University of Oxford, UK

  3. 4

    Cancer Research, UK

  4. 5

    Queen Mary University of London, UK

  5. 6

    Department of Clinical Pharmacology, University of Oxford, Oxford, UK

  6. 7

    University of Arizona College of Medicine, Tuscon, AZ, USA

  7. 8

    Southern Arizona VA Health Care System, USA

  8. 9

    Rhodes Professor of Cancer Therapeutics and Clinical Pharmacology, University of Oxford, UK

  9. 10

    University of Oxford, UK

  10. 11

    Murray F. Brennan Chair in Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA

  11. 12

    Weill Cornell Medical Center, New York, USA

Author Information

  1. Department of Surgery, Klinikam rechts der Isar, Technical University of Munich, Munich, Germany

Publication History

  1. Published Online: 14 JAN 2009
  2. Published Print: 11 APR 2008

ISBN Information

Print ISBN: 9781405127837

Online ISBN: 9781444300147

SEARCH

Keywords:

  • hepatobiliary cancer - 2molecular biology;
  • hepatocellular carcinoma (HCC);
  • pancreas and neuroendocrine tumors;
  • hereditary endocrine pancreatic tumors and von Hippel–Lindau disease (VHL);
  • cholangiocellular carcinoma;
  • Vascular endothelial growth factor (VEGF) and neoangiogenesis;
  • cholangiocellular cancers and Opisthorchis infections

Summary

This chapter contains sections titled:

  • References